ClinicalTrials.gg
RecruitingNCT07062575Updated Jun 2, 2026

Exoskeleton Training at Home to Assist Participants With Spinal Cord Injuries to Perform Ambulatory Functions.

An interventional study of ABLE Daily in Spinal Cord Injury, sponsored by ABLE Human Motion S.L.. Recruiting at 1 site in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-02.

Sponsored by ABLE Human Motion S.L. · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies in Spinal Cord Injuries with a site in Netherlands — 5 open to participants now, 6 under way, none of them phase 3. Spinal Cord Injuries · Netherlands.

Planned enrollment
12th of 18
10 · median 18
Started
2025
with 1 other
No phase
17 of 22
5 open now
Registered
20th of 22
by date
Lead sponsor
1 of 22
ABLE Human Motion S.L.

Among the 22 studies in Spinal Cord Injuries with a site in Netherlands, this one is the 12th largest by planned enrollment of the 18 interventional ones that give a count, is one of 2 that started in 2025, is one of 17 with no phase, and was the 20th registered.

Spinal Cord Injuries

2,032 studies on the registry are indexed under Spinal Cord Injuries; 542 are open to participants now.

Browse Spinal Cord Injuries studies →

Open to participants now

5 of the 22 studies in Spinal Cord Injuries with a site in Netherlands are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 374 Spinal Cord Injuries studies recruiting now, 167 (45%) set no upper age limit and 156 (42%) stop at 75 or younger; 40 take children under 18; 52 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Spinal Cord Injuries with a site in Netherlands, or all of them as a file.
02

Study summary

The goal of this clinical trial is to to confirm the safety and performance of the ABLE Daily to perform ambulatory functions in home and community settings for people with spinal cord injury.

The experimental period will cover the training period with the ABLE Daily exoskeleton (3 weeks of use at the investigational site with a total of 9 sessions) and the home period (12 weeks of personal use at home and community environments).

Read the detailed description

The ABLE Daily Exoskeleton is a wearable powered lower-limb exoskeleton that actively assists individuals with spinal cord injury to stand up, walk, ascend and descend a ramp of 5 degrees and sit down. The device consists of a rigid brace that attaches to the torso, legs and feet of the user via straps and supports. It is a bilateral robotic exoskeleton with four battery-powered motors that drive the knee and hip joints assisting in flexion-extension. The other degrees of freedom of the hip and knee joints are restricted. The ankle joint of the exoskeleton is passively articulated with a spring within a limited range of motion.

The experimental period will cover the training period happening at the investigational site where the participants and their companions will be trained 3 times a week. They will then have to perform a community skills test, if passed they will be allowed to take the exoskeleton home and use it in their daily life for 12 weeks. Pre and post assessments will be made.

03

Conditions studied

  • Spinal Cord Injury
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At least 18 years old
  • Chronic SCI (>6 months)
  • Injury at levels T1 to L5 (AIS A to D)
  • Walking Index for Spinal Cord Injury (WISCI) score 0 until 9
  • Height between 150-200 cm
  • Weight less than 100 kg
  • Capable of giving on their own
  • Able to train (at least) 3 days/week
  • Able to have at least 1 companion / buddy who can attend a minimum of two of the training sessions, besides the final assessment, and who will learn how to assist them at home and in the community (ideally two companions)
  • Proficiency in walking with the ABLE Exoskeleton
  • At least 8 weeks with minimal use (less than 5 sessions) of wearable robotic exoskeletons for gait assistance at the start of the study.

Exclusion criteria

Exclusion Criteria:

  • High risk of fractures due to osteoporosis, a dual energy X-ray absorptiometry (DEXA)-scan at the hip, distal femur, and proximal tibia BMD score
  • Fragility fractures of the lower limbs in the last 2 years
  • Deterioration >3 in the International Standards for Neurological Classification of SCI (ISNCSCI) score in the last 4 weeks
  • Spinal instability, like spondylolisthesis
  • Disorders of the arms and hands that make walking with crutches impossible
  • Modified Ashworth Scale (MAS) >3 in lower limbs
  • Cardiovascular health issues which prevent the participant from training
  • Instability to tolerate 10 minutes of standing without clinical symptoms of orthostatic hypotension
  • Psychological, cognitive issues, or any other condition that does not allow a participant to follow study procedures
  • Medically unstable due to severe comorbidities, including any condition that a physician deems inappropriate for completing study participation
  • Skin problems in areas that would be in contact with the device
  • Height, width, weight, or other anatomical limitations (such as differences in leg length) incompatible with the device
  • Insufficient joint range of motion (ROM) for the device
  • Known pregnancy
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    Intervention with exoskeleton

    The participants will receive training sessions with the ABLE Daily at Sint Maartenskliniek. After they pass the skills and knowledge exam, they will receive the ABLE Daily at their disposal at home for twelve weeks.

    Device: ABLE Daily

Interventions

  • DeviceABLE Daily

    The participants will receive training sessions with the ABLE Daily at Sint Maartenskliniek. After they pass the skills and knowledge exam, they will receive the ABLE Daily at their disposal at home for twelve weeks

06

What researchers measure

Primary outcomes

  1. Safety of the device

    The total number of adverse events and serious adverse events related to the investigational device at the end of the study will be measured.

    Time frame: Through study completion (up to 16 weeks)

  2. Performance of the device during the training period

    The number and type of device errors or use errors during the training period.

    Time frame: Through the training period (up to 3 weeks) from training session 1-9

  3. Performance of the device in the home/community period

    The amount of use of the device during the home/community use period, as measured by the number of sessions and the walking time, number of steps, and distance walked per session.

    Time frame: Through the home/community period (up to 12 weeks)

  4. Performance of the device in the home/community period

    The usability of the device as measured by the purpose and location of use of the device during the home/community use period which will be registered in a logbook by the participant.

    Time frame: Through the home/community period (up to 12 weeks)

  5. Performance of the device in the home/community period

    The number and type of device errors at the end of the home/community use period will be registered.

    Time frame: Through the home/community period (up to 12 weeks)

Secondary outcomes

  1. Perceived health status

    The change from baseline to final assessment of the overall perceived health status of the participants, as measured by the scores of the 36-Item Short Form Survey Instrument (SF-36). Scores for the different domains are converted and pooled using a scoring key, for a total score indicating a range of low to high Quality of Life. Lower scores indicate more disability, while higher scores indicate less disability.

    Time frame: At baseline and the final assessment at end of the study (16 weeks)

  2. Gait performance while using the device (6MWT)

    The change from the Community Skills Test to the final exoskeleton assessment of the 6-Minute Walk Test (6MWT). The outcome will be the distance walked during the 6 minutes after the training period and once again after the home period.

    Time frame: After training period (3 weeks) and at the final assessment at the end of the study (16 weeks)

  3. User satisfaction

    The general user satisfaction of participants, companions, and therapists at the end of the study, as measured by the scores of the Quebec User Evaluation of Satisfaction with assistive Technology (QUEST 2.0). 12 item instrument used to assess satisfaction with a specific assistive device; eight of these items assess characteristics of that assistive device and the remaining four items assess service and include: 1. Service delivery 2. Repairs and service of the device 3. Professionalism of service 4. Follow-up service Participants are asked to rate their satisfaction for the device on a five point scale that ranges from "not satisfied" at all to "very satisfied." Finally, participants are asked to choose the three most important items related to the assistive device in question System Usability Scale (SUS) to measure the perceived usability of the device. The scales value from 0 to 4 (with four being the most positive response).

    Time frame: At the final assessment at the end of the study (16 weeks)

  4. Gait performance using the device: 10-Meter Walk Test (10MWT)

    The 10 meter walk test will be used to compare performance after the training period and once again after the home period to monitor any changes in speed.

    Time frame: After training period (3 weeks) and at the final assessment at the end of the study (16 weeks)

Other outcomes

  1. Cardiovascular health

    Blood draw test to check levels of high-density lipoprotein cholesterol (HDL-c), Low-Density Lipoprotein Cholesterol (LDL-c), Triglyceride (TG), and Total Cholesterol (TC). Improvement is indicated with lower values of LDL-c and lower Triglycerides

    Time frame: Baseline assessment and at the final assessment at the end of the study (16 weeks)

  2. Respiratory Parameters

    Spirometry to assess the force vital capacity (FVC). FVC is crucial for evaluating lung function and respiratory and global health. Improvement indicates higher values of FVC.

    Time frame: Baseline assessment, during the 6 minute walk test and at the final assessment at the end of the study (16 weeks)

  3. Spasticity

    Visual analog scale (VAS) is a self-report tool that allows individuals to rate their perceived level of spasticity on a continuous scale, typically ranging from 0 to 10, where higher scores indicate greater severity. Spasticity is a complex phenomenon that can vary greatly in intensity and impact from person to person. The VAS provides a means for individuals to subjectively quantify and communicate their experience of spasticity, capturing nuances that may not be fully captured by objective measures alone. 0 indicated no spasticity and 10 indicates the most spasticity experienced.

    Time frame: Baseline assessment, end of training period (3 weeks), final assessment at the end of the study (16 weeks)

  4. Bowel and bladder management (SCI-QOL)

    Bladder Management Difficulties and Bowel Management Difficulties items from the Spinal Cord Injury - Quality of Life (SCI-QOL) questionnaire. The SCI-QOL questionnaire is a validated measure specifically designed to assess the quality of life in individuals with SCI across various domains, including bladder and bowel function

    Time frame: Baseline assessment and at the final assessment at the end of the study (16 weeks)

  5. Body composition using BMI

    Body weight provides valuable information about body composition. Body Mass Index (BMI) is a simple and straightforward measure calculated using an individual's weight and height. BMI provides a numerical value that categorizes individuals into different weight status categories, such as underweight, normal weight, overweight, or obese.

    Time frame: Baseline assessment and at the final assessment at the end of the study (16 weeks)

  6. Insulin Sensitivity

    Blood draw test to obtain the homeostatic model assessment (HOMA-IR), an indirect method to quantify insulin resistance and pancreatic β-cell function. HOMA-IR is a mathematical model used to estimate insulin resistance based on fasting glucose and insulin levels. Higher values indicate higher insulin resistance therefore an improvement would be a lower value.

    Time frame: Baseline assessment and at the final assessment at the end of the study (16 weeks)

  7. Sleep

    The 8-item PROMIS (Patient-Reported Outcomes Measurement Information System) Sleep-Related Impairment questionnaire to measure alertness, sleepiness, tiredness, and functional impairments associated with sleep problems during waking hours. It assesses sleep disturbance over the past seven days. PROMIS instruments are scored using item-level calibrations on a 5 point likert scale from not at all to very much. Higher T-scores indicate greater sleep disturbance.

    Time frame: Baseline assessment and at the final assessment at the end of the study (16 weeks)

  8. Body Composition: Waist circumference

    Waist circumference measures the circumference of the waist at a specific point, typically at the level of the natural waist or the midpoint between the lower rib and the iliac crest. Lower values indicate better health.

    Time frame: Baseline assessment and at the final assessment at the end of the study (16 weeks)

  9. Respiratory Parameters

    Spirometry to assess the forced expiratory volume in 1 second (FEV1). FEV1 is crucial for evaluating lung function and respiratory and global health. A higher value indicates better respiratory function

    Time frame: Baseline assessment, during the 6 minute walk test and at the final assessment at the end of the study (16 weeks)

  10. Respiratory Parameters

    Spirometry to assess the forced expiratory flow (FEF). FEF is crucial for evaluating lung function and respiratory and global health. A higher value indicates better respiratory function.

    Time frame: Baseline assessment, during the 6 minute walk test and at the final assessment at the end of the study (16 weeks)

  11. Respiratory Parameters

    Spirometry to assess the peak expiratory flow (PEF). PEF is crucial for evaluating lung function and respiratory and global health. A higher value

    Time frame: Baseline assessment, during the 6 minute walk test and at the final assessment at the end of the study (16 weeks)

  12. Respiratory Parameters

    Spirometry to assess the maximal voluntary ventilation (MVV). MVV is crucial for evaluating lung function and respiratory and global health. A higher value would indicate better lung function.

    Time frame: Baseline assessment, during the 6 minute walk test and at the final assessment at the end of the study (16 weeks)

  13. Bowel and bladder management (BSS)

    The Bristol Stool Scale categorizes stool consistency into seven distinct types, ranging from hard lumps (Type 1) to watery diarrhea (Type 7), based on visual descriptions and illustrations. The BSS provides a standardized and objective method for individuals to describe their stool consistency, facilitating communication with healthcare providers.

    Time frame: Baseline assessment and at the final assessment at the end of the study (16 weeks)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Oct 2026, 16 months after the start.

Of 49 industry-sponsored interventional studies with no phase under Spinal Cord Injuries, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 28. This study's planned 16 months is close to that.

Counting every sponsor, half of 840 studies reached it within 36 months; a quarter within 17 and three quarters within 64.

How these figures are worked out, and which studies are left out of them.

Registered
May 26, 2025
First posted
Jul 14, 2025
StartActual
Jun 19, 2025
Primary completionEst.
Oct 30, 2026
CompletionEst.
Oct 30, 2026
Last update
Jun 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07062575
Lead sponsor
ABLE Human Motion S.L.
Collaborators
Sint Maartenskliniek, Universitat Politècnica de Catalunya
Responsible party
Sponsor
First posted
Jul 14, 2025
Start date
Jun 19, 2025
Primary completion
Oct 30, 2026 (estimated)
Completion
Oct 30, 2026 (estimated)
Last update
Jun 2, 2026

Study contacts

Noel Keijsers
Contact
n.keijsers@maartenskliniek.nl
+ 31 6 44244217
Daphne Oosterling
Contact
d.oosterling@maartenskliniek.nl
Noel Keijsers
principal investigator · Sint Maartenskliniek

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion